CTRI/2018/06/014407已完成未知
Reducing risk factors of metabolic syndrome using a Unani personalized programme
ational Institute of Unani medicine0 个研究点目标入组 50 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients with three or more of the following features-3
- •1 Central obesity waist circumference > 90 cm in Male, >80 cm in Female
- •2 Hypertriglyceridemia; triglycerides >= 150 mg/dl
- •3 Low HDL cholesterol <40 mg/dl in males and <50 mg/dl in females
- •4 BP >=130/ 85 mmHg
- •5 Fasting plasma glucose >= 100mg/dl
排除标准
- •1 All types of heart, liver and kidney diseases
- •2 Pregnancy
- •3 Lactation
- •4 Type-1 Diabetes
- •5 Weight loss medication
- •6 Uncontrolled Diabetes type 2 and uncontrolled Hypertension.
研究者
相似试验
已完成
不适用
Effect of the modified Mediterranean diet for prevention of metabolic syndrome in patients undergoing liver transplantatioCondition 1: Metabolic Syndrome. Condition 2: Metabolic Syndrome. Condition 3: Metabolic Syndrome. Condition 4: Metabolic Syndrome. Condition 5: Metabolic Syndrome.Pure hyperglyceridaemiaEssential (primary) hypertensionElevated blood glucose levelAbnormal weight gainLipoprotein deficiencyIRCT2015012720841N1Vice-Chancellery of Research and Technology150
招募中
不适用
The intervention study about the metabolic syndrome in a rural villagemetabolic syndromeJPRN-UMIN000010611Ehime University Graduate School of Medicine100
已完成
不适用
Analysis of the metabolic syndrome improvement with the orexin receptor antagonistMetabolic syndrome with insomniaJPRN-UMIN000027445Kochi University
尚未招募
不适用
Characterisation of chylomicron size distribution in subjects with metabolic syndrome: The effect of dietary fatty acid composition.Metabolic syndromeMetabolic and Endocrine - Metabolic disordersACTRN12614000352606Curtin University, School of Public Health30
已完成
不适用
Intervention trials for prevention of metabolic dysfunction among patients with schizophreniaMetabolic syndrome among patints with schizophreniaJPRN-UMIN000014016Joint committee for antipsychotics treatment and physical risk540